More Optimism Around Sustainable Growth

Abbott Executive Vice President and Chief Financial Officer Brian Yoor explains how strategic shaping created a robust pipeline to fuel faster revenue growth.

Strategy and Strength | Mar. 15, 2019

Abbott's leadership has evolved the company prudently by investing in its own fast-growing medical technologies and by acquiring the right set of devices in the most promising areas of healthcare. The result: A global player with the richest pipeline of new offerings in its recent history, and investors are noticing.

The drivers behind the forecasted revenue growth of 6.5-7.5 percent this year include contributions from all Abbott businesses, said Brian Yoor, chief financial officer and executive vice president, at a Barclays investor conference. Abbott's FreeStyle Libre continuous glucose monitoring system, its Alinity diagnostics platforms and its fast-growing Mitraclip treatment to repair heart valves are just some of the technologies that are making a big impact.

"It's just an exciting time for Abbott, and it's exciting to have clear line of sight of where we're going and how we're getting there," Yoor said.

Sign up for Abbott Edge for latest on Coronavirus